NASDAQ · EDSA
Edesa Biotech, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for EDSA: Dec 11, 2026
Edesa Biotech, Inc. Common Shares is estimated to report earnings on 12/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.57. The reported EPS for the same quarter last year was $-0.32.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.57 | $-0.57 | $-0.58 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · The Motley Fool · Quiver Quantitative- Fintel · Oct 23, 9:08 PM EDTEdesa Biotech, Inc. Approves Executive Salary Increases Retroactive to July 1, 2026On October 23, 2026, the Board of Directors of Edesa Biotech, Inc. approved increases in the annual base salaries of its executive officers, upon the recommendation of the Board's Compensation Committee. The salary adjustments are retroactive to July 1, 2026, and represent the fi
- RTTNews · Oct 15, 10:13 AM EDTEdesa Secures FDA Clearance To Expand Phase 2 Vitiligo Trial Of EB06 Into U.S(RTTNews) – Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, reported that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for its Phase 2 clinical study of EB06 in vitiligo, allowing Edesa to
- RTTNews · Aug 20, 1:50 AM EDTEdesa Biotech Prices $25 Mln Public Offering Of Shares And Warrants; Stock Down(RTTNews) – Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, priced an underwritten public offering of 3.87 million shares with warrants to purchase 3.87 million additional shares, plus pre-funded warrants for up to 0.67 million shares at an exercise price
- RTTNews · Aug 19, 10:16 PM EDTEdesa Biotech Announces Proposed Public Offering; Stock Down(RTTNews) – Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced on Wednesday that it has commenced an underwritten public offering of its common shares, or pre-funded w
- RTTNews · Aug 18, 9:59 PM EDTAfter-Hours Biotech Gainers: TNON, BIVI, EDSA, RNAZ, HCWB(RTTNews) – Today's after-hours gainers include Tenon Medical, which recently reported its second-quarter results and implemented a reverse stock split; BioVie, which is developing a drug for early-stage Parkinson's disease; and Edesa Biotech, which is advancing EB06, a potential
- RTTNews · Jun 23, 11:13 PM EDTTop Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment(RTTNews) – Today's top gainers include Boundless Bio, which is combining with privately held Serapha; Monopar, on track for an NDA submission of ALXN1840 for Wilson disease; Jade Biosciences, advancing its autoimmune disease pipeline; and Galectin Therapeutics, which has reached
- RTTNews · Jun 12, 6:57 AM EDTEdesa Enters PIPE Placement Worth $3.5 Mln With Investors And CEO(RTTNews) – Edesa Biotech Inc. (EDSA), a clinical-stage biopharmaceutical company, on Thursday reported entering a Private Investment in Public Equity (PIPE) placement with healthcare-focused investors and the company's Chief Executive Officer (CEO).
- RTTNews · May 20, 5:01 AM EDTMTVA Gains Weight, CODX Takes A Shot At Ebola, EDSA To Reveal New Data, BDTX On Watch(RTTNews) – As hedge fund tycoon George Soros once said, "It's not whether you're right or wrong that's important, but how much money you make when you're right and how much you lose when you're wrong." The following biotech stocks were among the top gainers in Tuesday's trading
- Fintel · Nov 3, 7:05 PM ESTHC Wainwright & Co. Reiterates Edesa Biotech (EDSA) Buy RecommendationFintel reports that on November 3, 2025, HC Wainwright & Co. reiterated coverage of Edesa Biotech (NasdaqCM:EDSA) with a Buy recommendation. Analyst Price Forecast Suggests 502.28% Upside
- RTTNews · Oct 28, 8:59 AM EDTEdesa Biotech Reports Positive Phase 3 Results For Paridiprubart In ARDS(RTTNews) – Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, on Tuesday reported positive results from a Phase 3 study evaluating paridiprubart, its drug candidate for the treatment of Acute Respiratory Distress Syndrome (ARDS).
- The Motley Fool · Aug 8, 4:49 PM EDTEdesa Biotech Posts Narrower Loss in Q3Earnings per share (EPS) loss was $(0.25) (GAAP) for Q3 FY2025, beating the consensus estimate of $(0.26) and representing an improvement from $(0.52) (GAAP) in Q3 FY2024.
- Quiver Quantitative · May 14, 4:26 PM EDTEdesa Biotech Reports Q2 2025 Financial Results and Advances Vitiligo Drug Development EffortsEdesa Biotech reports financial updates, equity financing for vitiligo drug, and plans for Phase 2 study in 2025.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Edesa Biotech, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.